Novo Nordisk | NVO - Betriebsaufwand





Betriebsaufwand Veränderung Datum
ANI Pharmaceuticals USD 217.93M 287.88M 2025-12
Aurora Cannabis CAD 129.98M 16.05M 2025-12
Bausch Health Companies USD 2.04B 42M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Canopy Growth CAD 87.2M 6.22M 2025-12
Corcept Therapeutics USD 214.5M 16.87M 2026-03
Drreddys Laboratories INR 72.94B 4.33B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Merck USD 18.17B 8.01B 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Novartis USD 9.29B 507M 2026-03
Novo Nordisk DKK 46.76B 3.99B 2025-12
Novo Nordisk DKK 6.5B 32.8B 2025-06
Pacira USD 172.75M 20.93M 2026-03
Perrigo USD 1.03B 75.3M 2025-12
Phibro Animal Health USD 332.36M 20.68M 2025-12
Prestige Brands USD 200.95M 6.51M 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
Supernus Pharmaceuticals USD 1.08B 879.06M 2026-03
Zoetis USD 1.55B 3.85B 2025-12